About Stratpharma
Stratpharma Switzerland -
Heal Better™
Stratpharma Switzerland
Heal Better™
Stratpharma Switzerland, based in Basel since 2005, is a global medical devices and pharmaceutical company.
Our first-class teams design, develop, manufacture and market breakthrough products for patients around the world.
Mission
Our mission is to use innovative methods to deliver medical solutions in the fields of aesthetic medicine, dermatology and plastic surgery, advanced wound care, women’s health, and oncology supportive care. To achieve this, we partner with leading medical institutions and developers of cutting-edge technologies to combine science and innovation. We will deliver our treatments to international markets under a single Global Branding Platform supported by first level clinical evidence.
Vision
Our vision is to deliver innovative products that meet directly the needs of our customers making them “The Gold Standard” for performance and value.
Our values
Challenge
We challenge industry structures and “road blocks” that impede the rapid delivery of quality medical devices and pharmaceutical products to patients and healthcare professionals on a global basis.
Best Value
We drive out cost from the value chain so that we can deliver “best value” products to our final customers.
Integrity
We demand and expect the highest standards of integrity and professionalism from our staff and our value chain partners.
Patients enrolled in Stratpharma post-marketing surveillance studies.
The year Stratpharma was founded.
Countries worldwide with distribution and still growing
Languages spoken in the Stratpharma headquarters.
Our History
2005
Stratpharma is born
Establishment of Stratpharma GmbH in Basel Switzerland.
2008
Launch of Strataderm
Establishment of Stratpharma AG.
Launch of our first product, Strataderm - For professional scar therapy.
2009
Launch of Stratamed
A breakthrough in wound healing for faster healing and early abnormal scar prevention.
First international sales.
Distribution in 8 countries.
ISO 13485 certification.
2010
Expansion
Distribution in 13 countries.
2012
First international clinical publication
Distribution in 16 countries.
First international clinical publication.
Doubling the number of employees.
2013
Launch of Stratamark
A breakthrough in the prevention and treatment of stretch marks.
Distribution in 18 countries.
2014
Launch of StrataXRT
A breakthrough in the prevention and treatment of radiation dermatitis.
Distribution in 23 countries.
2015
Distribution in 40 countries
Sales in all 5 continents.
First direct marketing model established in Australia.
2016
Launch of Stratacel
A breakthrough in post-procedure care.
Distribution in 44 countries.
2016
Stratpharma, Inc. USA
Opening of the U.S. subsidiary. This marked a key milestone in the company’s international expansion and strengthened its presence in a strategic market.
2017
Continuous progress
More than 8 novel products under development in our pipeline.
14 languages are spoken in Stratpharma's headquarters.
More than 20 collaborations with universities and research institutions.
2018
Stratpharma Pty. Ltd. Australia
Opening of the Australian subsidiary. This expansion helped consolidate the company’s activity in the Asia-Pacific region and bring it closer to new customers.
2019
Launch of StrataCTX
A non-steroidal gel for the management of dry skin and cutaneous rashes.
2022
Stratpharma Limited, Ireland
This launch supported the strengthening of the company’s European operations.
2023
Launch of StrataMGT
A non-hormonal and non-steroidal gel for vaginal atrophy and lichenoid dermatoses (sclerosus / planus).
2023
Stratpharma Iberia, S.L.
Opening of the Iberia subsidiary. This development helped expand the company’s commercial presence in the Iberian market.
2024
Stratpharma Romania and Greece
Stratpharma Romania S.R.L. - Stratpharma Hellas (Ιατροτεχνολογικά Προϊόντα Μονοπρόσωπη Ε.Π.Ε.)
Opening of the Romanian and Greek subsidiaries. These new locations supported the company’s growth in Southeastern Europe.
2025
Stratpharma China and Japan
Stratpharma Nippon GK (合同会社) / 广州市施可复医疗科技有限公司 (Guangzhou Stratpharma Medical Technology Co., Ltd.)
Opening of the Japanese and Chinese subsidiaries. These developments strengthened the company’s footprint in Asia and confirmed its international ambition.
2026
Launch of Colsigen
ADVANCED SKIN RECOVERY - Featuring Humanized Type III Collagen to
restore, renew and rejuvenate compromised
and injured skin following cosmetic procedures.
Quality and Control
Our products are classified as medical devices and comply with international safety and quality standards.
ISO 13485 Certified: For the design, development and manufacturing of topical Silicone medical devices for dermatological and wound care applications.
Our medical devices comply with the regulatory requirements of major health authorities worldwide.
Global Presence & Registrations
- Active countries
- Active countries with subsidiaries
Marketing Authorization
80+ Countries
Product Sales
70+ Countries
Business Development
35+ Countries
Basel - a modern city with tradition
Stratpharma’s headquarters is located in Basel, a city with a long cultural and scientific history, which led to the establishment of a unique quality of life and a prosperous economy.
Basel lies in the heart of Europe on the banks of the river Rhine. It is the point of contact of France, Germany and Switzerland which makes this location unique.
The creation and arrival of leading international companies, research institutes and academic institutions, made the city evolve towards a cosmopolitan culture and an international environment. Basel managed the perfect merge of tradition and modernity to create a lively and unique atmosphere.
Basel is home to some of the world’s biggest pharmaceutical companies, which pioneer in research and development within the industry. This has led to a dynamic development of the economy in Basel which attracted a great number of experts from all over the world.
That is why this stirring environment is the ideal location for Stratpharma’s headquarters. We are building on experience to create a successful future.
Our commitments
Stratpharma’s Modern Slavery Statement
This statement outlines the steps Stratpharma AG (including its subsidiaries) has taken to prevent modern slavery and human trafficking in our business operations and supply chain.
Carbon reduction plan
Stratpharma is committed to achieving net zero emission by 2049